0.7089
price down icon8.60%   -0.0667
after-market Dopo l'orario di chiusura: .70 -0.0089 -1.26%
loading
Precedente Chiudi:
$0.7756
Aprire:
$0.694136
Volume 24 ore:
321.00K
Relative Volume:
0.07
Capitalizzazione di mercato:
$21.41M
Reddito:
-
Utile/perdita netta:
$-29.77M
Rapporto P/E:
-0.0463
EPS:
-15.2954
Flusso di cassa netto:
$-24.23M
1 W Prestazione:
+10.77%
1M Prestazione:
+158.82%
6M Prestazione:
-59.72%
1 anno Prestazione:
-80.09%
Intervallo 1D:
Value
$0.6871
$0.7163
Intervallo di 1 settimana:
Value
$0.655
$0.96
Portata 52W:
Value
$0.25
$3.7044

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name
Nome
Moleculin Biotech Inc
Name
Telefono
713-300-5160
Name
Indirizzo
5300 MEMORIAL DRIVE, HOUSTON, TX
Name
Dipendente
17
Name
Cinguettio
@moleculinbio
Name
Prossima data di guadagno
2024-12-08
Name
Ultimi documenti SEC
Name
MBRX's Discussions on Twitter

Confronta MBRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
MBRX
Moleculin Biotech Inc
0.7089 23.43M 0 -29.77M -24.23M -15.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-09 Ripresa H.C. Wainwright Buy
2025-02-12 Downgrade Maxim Group Buy → Hold
2022-07-18 Ripresa Oppenheimer Outperform

Moleculin Biotech Inc Borsa (MBRX) Ultime notizie

pulisher
Jul 23, 2025

Moleculin Biotech Inc. Stock Analysis and ForecastTremendous portfolio expansion - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is Moleculin Biotech Inc. a good long term investmentConsistent triple-digit returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

Moleculin Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times

Jul 22, 2025
pulisher
Jul 22, 2025

Exclusive: Moleculin CEO Shares Vision Behind Revolutionary Cancer Drug Pipeline in New Investor Presentation - Stock Titan

Jul 22, 2025
pulisher
Jul 21, 2025

Moleculin Biotech Gains Approval for Phase 2B/3 AML Study - MSN

Jul 21, 2025
pulisher
Jul 21, 2025

What drives Moleculin Biotech Inc. stock priceConsistently high returns - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

What analysts say about Moleculin Biotech Inc. stockMassive wealth growth - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 18, 2025

Moleculin Biotech Appoints Adriano Treve as Strategic Advisor - The Globe and Mail

Jul 18, 2025
pulisher
Jul 17, 2025

MBRX Surges 29.65% on Strategic Hire and Phase 3 Momentum – Is This the Catalyst for a Biotech Breakout? - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

Moleculin appoints former Roche executive as strategic advisor - Investing.com Australia

Jul 17, 2025
pulisher
Jul 17, 2025

Moleculin appoints former Roche executive as strategic advisor By Investing.com - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Moleculin Biotech, Inc. Appoints Adriano Treve as Strategic Advisor to Enhance Partnerships and Advance Clinical Trials - Nasdaq

Jul 17, 2025
pulisher
Jul 17, 2025

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships - GlobeNewswire

Jul 17, 2025
pulisher
Jul 15, 2025

What makes Moleculin Biotech Inc. stock price move sharplySmart Trading With Safety Margin - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Moleculin Biotech Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Moleculin Biotech Surges 19.5%—What's Fueling the Rally? - AInvest

Jul 14, 2025
pulisher
Jul 11, 2025

Moleculin Biotech enters $6.5 million at-the-market equity offering agreement By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Moleculin Biotech Enters New Stock Offering Agreement - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

Moleculin Biotech enters $6.5 million at-the-market equity offering agreement - Investing.com

Jul 11, 2025
pulisher
Jul 10, 2025

Moleculin Acquires $2M Private Grant for Brain Tumor Trial at MD Anderson - BioTecNika

Jul 10, 2025
pulisher
Jul 10, 2025

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans - GlobeNewswire

Jul 10, 2025
pulisher
Jul 09, 2025

Moleculin receives Georgian approval for pivotal AML treatment trial By Investing.com - Investing.com India

Jul 09, 2025
pulisher
Jul 09, 2025

Moleculin receives Georgian approval for pivotal AML treatment trial - Investing.com Australia

Jul 09, 2025
pulisher
Jul 09, 2025

Moleculin Biotech Stock Soars 13.44% on Clinical Trial Expansion - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Moleculin Biotech, Inc. Secures RAMPA Approval for Phase 2B/3 MIRACLE Trial in Georgia, Expanding Clinical Recruitment Efforts - Nasdaq

Jul 09, 2025
pulisher
Jul 09, 2025

MBRX gains RAMPA nod for pivotal Phase 2B/3 AnnAraC AML trial | THTX SEC FilingForm 6-K - Stock Titan

Jul 09, 2025
pulisher
Jul 09, 2025

Moleculin's Phase 3 AML Treatment Trial Gains Momentum: 7 Patients Treated, 16 New Sites Coming - Stock Titan

Jul 09, 2025
pulisher
Jul 03, 2025

Favourable Signals For Moleculin Biotech: Numerous Insiders Acquired Stock - simplywall.st

Jul 03, 2025
pulisher
Jun 27, 2025

Moleculin Biotech (MBRX) Price Target Reduced to $13 by Roth Cap - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

Moleculin Biotech Faces Nasdaq Delisting Warning - TipRanks

Jun 27, 2025
pulisher
Jun 26, 2025

Healthcare Stocks to Watch: Catalyst Pharmaceuticals, AVITA Medical, and Moleculin Biotech. - AInvest

Jun 26, 2025
pulisher
Jun 23, 2025

Moleculin Biotech Raises $5.9M in Public Offering - TipRanks

Jun 23, 2025
pulisher
Jun 21, 2025

Health Care Stocks Stumble Amid Market Adjustments - Finimize

Jun 21, 2025
pulisher
Jun 21, 2025

Moleculin Biotech prices 16.08M shares at 37c in public offering - Yahoo Finance

Jun 21, 2025
pulisher
Jun 20, 2025

Moleculin Biotech prices $5.9M public offering; shares down about 47% - MSN

Jun 20, 2025
pulisher
Jun 20, 2025

Moleculin Biotech's 50% Plunge Explained: Technical Sell-Off Dominates - AInvest

Jun 20, 2025
pulisher
Jun 19, 2025

Moleculin Biotech (NASDAQ:MBRX) Given Buy Rating at HC Wainwright - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

Moleculin Biotech (MBRX) Rating Reiterated with $4.00 Price Target | MBRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML - GlobeNewswire

Jun 18, 2025

Moleculin Biotech Inc Azioni (MBRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):